Received Oct 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | 3 | U8574AA | OT / RA |
was supposed to get bexsero but was given a second dose of menquadfi instead with no adverse event; inadvertently gave 3rd dose of meningococcal vaccine to the patient with no adverse event; Initial information received on 08-Oct-2025 regarding an unsolicited valid non-serious case received from a physician. This case involves a 16 years old female patient who was supposed to get Meningococcal Vaccine B Rfhbp/Nada/Nhba Omv [BEXSERO] but was given a second dose of Meningococcal A-C-Y-W135 (T Conj) Vaccine [Menquadfi] Instead and inadvertently received with 3rd dose of same vaccine with no adverse event. The patient's past vaccination(s) included Menactra [Meningococcal Vaccine A/C/Y/W Conj (Dip Tox)] when the she was 11 years old. The patient's past medical history, medical treatment(s) and family history were not provided. On an unknown date, the patient received dose 1 of suspect Meningococcal A-C-Y-W135 (T Conj) Vaccine, Solution for injection, lot number, expiry date and strength not reported via unknown route in unknown administrative site for Meningococcal Disease (Meningococcal immunisation). On an unknown date, the patient was supposed to get bexsero but was administered with dose 2 of suspect Meningococcal A-C-Y-W135 (T Conj) Vaccine, Solution for injection, lot number, expiry date and strength not reported via unknown route in unknown administrative site for Meningococcal Disease (Meningococcal immunization), instead with no adverse event (wrong product administered) (latency: same day). On 07-Oct-2025 the patient was inadvertently administered dose 3 of suspect Meningococcal A-C-Y-W135 (T Conj) Vaccine, Solution for injection, lot number: U8574AA,strength:standard, expiry date not reported via intramuscular route in the right arm for Meningococcal Disease [Meningococcal immunization], with no adverse event (extra dose administered) (latency: same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.